Testing a new imaging agent for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new imaging agent called 68Ga-NOTA-SCH001 to see if it can help detect multiple myeloma. It also looks at how safe the agent is and how it spreads in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma
- You are 18 years or older
- You are able to lie still for about 30 minutes for scans
- You have not received certain antibody therapy (called CD38 monoclonal antibody) before joining
- You are willing to use effective birth control if needed
- You do not have active infections, other serious illnesses, or severe mental health conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging agent that may help doctors see multiple myeloma more clearly. It uses a special radioactive tracer that targets a protein found on myeloma cells, which could improve diagnosis and monitoring of the disease.
This trial tests a new drug called SCTC21C combined with standard treatments (bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see if this combination is safe and works better than current options.
This trial tests a new drug called QI-019A for people whose multiple myeloma has returned or stopped responding to at least two prior treatments. The goal is to see if it is safe and if it can help control the disease.
This trial tests a new drug called SHR-9539 for people with multiple myeloma, a type of blood cancer. The goal is to see if it is safe and how it affects the cancer.
This trial tests a special imaging dye that targets a protein called BCMA on multiple myeloma cells. It may help doctors see and diagnose the disease more clearly during bone marrow or tissue biopsies.
This Phase 1 study tests a new special scan marker (a radioactive imaging agent) to see whether it can detect certain multiple myeloma spots in the body. If it works, it may help doctors better locate disease using a PET-style scan.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.